Table 2 Unadjusted risk of inpatient mortality, length of stay in hospital, and healthcare expenditures for chemotherapy- induced neutropenic complications requiring inpatient care, by duration of filgrastim prophylaxis
Days of Filgrastim Prophylaxis | |||
|---|---|---|---|
1-3 | 4-6 | > = 7 | |
Mortality, % (95% CI) | 8.4 (4.6-14.8) | 4.0 (1.4-11.1) | 0.0 (0.0-10.2) |
(n = 119) | (n = 75) | (n = 34) | |
LOS (days), mean (95% CI) | 7.4 (6.4-8.3) | 7.1 (5.7-8.5) | 6.5 (4.9-8.0) |
(n = 243) | (n = 99) | (n = 40) | |
Expenditures, mean (95% CI) | |||
Inpatient | $18,509 (14,195-23,145) | $14,527 (10,758-19,243) | $12,544 (9,063-16,315) |
Outpatient | $226 (126–350) | $356 (148–630) | $581 (145–1,180) |
Pharmacy | $177 (68–329) | $24 (13–39) | $41 (10–88) |
Total | $18,912 (14,570-23,581) | $14,907 (11,155-19,728) | $13,165 (9,595-17,144) |
(n = 225) | (n = 94) | (n = 39) | |